Focused Wealth Management Has Decreased Gilead Sciences (GILD) Stake; Nuveen Amt-free Municipal Value Fund (NUW) Has 1.46 Sentiment

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Nuveen Amt-free Municipal Value Fund (NUW) investors sentiment increased to 1.46 in 2018 Q3. It’s up 0.32, from 1.14 in 2018Q2. The ratio is positive, as 67 institutional investors started new or increased holdings, while 46 trimmed and sold stakes in Nuveen Amt-free Municipal Value Fund. The institutional investors in our database now have: 45.04 million shares, up from 42.40 million shares in 2018Q2. Also, the number of institutional investors holding Nuveen Amt-free Municipal Value Fund in top ten holdings was flat from 5 to 5 for the same number . Sold All: 14 Reduced: 32 Increased: 38 New Position: 29.

Focused Wealth Management Inc decreased Gilead Sciences Inc (GILD) stake by 32.82% reported in 2018Q3 SEC filing. Focused Wealth Management Inc sold 8,107 shares as Gilead Sciences Inc (GILD)’s stock declined 6.92%. The Focused Wealth Management Inc holds 16,594 shares with $1.28M value, down from 24,701 last quarter. Gilead Sciences Inc now has $87.75 billion valuation. The stock decreased 0.16% or $0.11 during the last trading session, reaching $67.83. About 1.55M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 7.19% since January 10, 2018 and is downtrending. It has underperformed by 7.19% the S&P500. Some Historical GILD News: 30/05/2018 – GILEAD: EQUATOR ACHIEVES PRIMARY ENDPOINT; 16/04/2018 – GILD: NEW: SCOTUS asks the solicitor general to weigh in on a False Claims Act petition (Gilead Sciences Inc. v. U.S. es rel. Campie, No. 17-936). The materiality issue raised in that case could affect a related retaliation claim brought by the employee; 30/05/2018 – REG-GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS; 23/03/2018 – Gilead TAF Sales Rise 3%, HIV Combo Pills Gain 2%; 30/05/2018 – GALAPAGOS NV – IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER; 15/05/2018 – Gilead Presenting at Bank of America Conference Tomorrow; 13/03/2018 – QUEBEC EXPANDS PATIENT ACCESS TO CHRONIC HEPATITIS C THERAPIES; 05/03/2018 – GLAXOSMITHKLINE PLC – VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS; 23/04/2018 – Gilead’s Descovy Falls After 2-Wk Rise, Triumeq Declines: HIV; 17/05/2018 – FDA names drugmakers potentially acting to delay cheap generics

Karpus Management Inc. holds 3.75% of its portfolio in Nuveen AMT-Free Municipal Value Fund for 7.34 million shares. Rivernorth Capital Management Llc owns 3.28 million shares or 3.47% of their US portfolio. Moreover, Robinson Capital Management Llc has 2.93% invested in the company for 772,806 shares. The Texas-based Oxbow Advisors Llc has invested 2.22% in the stock. Jfs Wealth Advisors Llc, a Pennsylvania-based fund reported 323,621 shares.

The stock 0.03% or $0 during the last trading session, reaching $15.23. It is down 14.87% since January 10, 2018 and is downtrending. It has underperformed by 14.87% the S&P500.

Focused Wealth Management Inc increased Spdr Series Trust stake by 24,156 shares to 778,160 valued at $24.22M in 2018Q3. It also upped At&T Inc (NYSE:T) stake by 28,899 shares and now owns 47,030 shares. Invesco Exchange Traded Fd T was raised too.

Among 6 analysts covering Gilead Sciences (NASDAQ:GILD), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Gilead Sciences had 8 analyst reports since July 26, 2018 according to SRatingsIntel. On Friday, October 26 the stock rating was downgraded by PiperJaffray to “Neutral”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Equal-Weight” rating given on Wednesday, December 19 by Morgan Stanley. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Equal-Weight” rating by Morgan Stanley on Thursday, July 26. Robert W. Baird downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, July 26 to “Neutral” rating. Raymond James maintained the stock with “Strong Buy” rating in Friday, October 26 report. The stock has “Outperform” rating by Oppenheimer on Thursday, January 3. The rating was maintained by Cantor Fitzgerald with “Overweight” on Friday, October 26.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 5. They expect $1.63 EPS, up 1.87% or $0.03 from last year’s $1.6 per share. GILD’s profit will be $2.11 billion for 10.40 P/E if the $1.63 EPS becomes a reality. After $1.70 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -4.12% negative EPS growth.

Since September 4, 2018, it had 0 insider purchases, and 4 sales for $14.65 million activity. $3.90M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart